Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?

abstract：:Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

journal_title：Expert review of anticancer therapy

authors： Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

更新日期：2014-01-01 00:00:00

abstract：:Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

journal_title：Expert review of anticancer therapy

authors： Roussos Torres ET,Epstein AL

更新日期：2021-01-19 00:00:00

abstract：:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

journal_title：Expert review of anticancer therapy

authors： Lang JE,Hall CS,Singh B,Lucci A

更新日期：2007-10-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：:Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

journal_title：Expert review of anticancer therapy

authors： Hussein MR,Baidas S

更新日期：2002-10-01 00:00:00

abstract：:Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. ...

journal_title：Expert review of anticancer therapy

authors： Sirohi B,Powles R

更新日期：2009-11-01 00:00:00

abstract：:Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

journal_title：Expert review of anticancer therapy

authors： Popovtzer A,Eisbruch A

更新日期：2008-04-01 00:00:00

abstract：:Novel targeted agents, such as VEGF receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and mTOR inhibitors, have improved therapy for metastatic renal cell carcinoma. Sequential administration of agents with similar mechanisms of action has shown some efficacy in small retrospective studies; however, prospective Phase I...

journal_title：Expert review of anticancer therapy

authors： Larkin J,Swanton C,Pickering L

更新日期：2011-04-01 00:00:00

abstract：:Testicular germ cell tumors are the most frequent solid tumor to affect young adult males and are increasing in incidence for reasons that are poorly understood. Increasingly, patients present with localized disease where disease-specific survival approaches 100%. Even in the presence of metastatic disease, the majori...

journal_title：Expert review of anticancer therapy

authors： Gilbert DC,Van As NJ,Huddart RA

更新日期：2009-02-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00

abstract：:Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

journal_title：Expert review of anticancer therapy

authors： Ward JF,Blute ML

更新日期：2003-04-01 00:00:00

abstract：:Estrogens are involved in numerous physiological processes and have crucial roles in certain disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is found in breast tissue and the i...

journal_title：Expert review of anticancer therapy

authors： Brueggemeier RW

更新日期：2002-04-01 00:00:00

abstract：:Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

journal_title：Expert review of anticancer therapy

authors： MacDonald IC,Chambers AF

更新日期：2006-09-01 00:00:00

abstract：:With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

journal_title：Expert review of anticancer therapy

authors： Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several o...

journal_title：Expert review of anticancer therapy

authors： Alphandéry E,Grand-Dewyse P,Lefèvre R,Mandawala C,Durand-Dubief M

更新日期：2015-01-01 00:00:00

abstract：:Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

journal_title：Expert review of anticancer therapy

authors： Kim KB,Khuri FR,Shin DM

更新日期：2001-06-01 00:00:00

abstract：:Advanced gastric cancer (GC) is a dreadful disease with a poor prognosis and the majority of patients die within 1 year of diagnosis. In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (ME...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O

更新日期：2015-02-01 00:00:00

abstract：:Anemia is a common and potentially debilitating complication of cancer. Darbepoetin alfa (Aranesp, Amgen) has been in routine clinical use for the treatment of chemotherapy-induced anemia since 2002. The extended half-life of darbepoetin alfa permits less frequent and consequently more flexible dosing than other eryth...

journal_title：Expert review of anticancer therapy

authors： Pirker R

更新日期：2004-10-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

journal_title：Expert review of anticancer therapy

authors： Smith KM,Desai J

更新日期：2018-07-01 00:00:00

abstract：INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

journal_title：Expert review of anticancer therapy

authors： Huang SB,Zheng CX

更新日期：2017-01-01 00:00:00

abstract：:With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

journal_title：Expert review of anticancer therapy

authors： Dixon JM

更新日期：2002-06-01 00:00:00

abstract：:Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

journal_title：Expert review of anticancer therapy

authors： Gulley J,Dahut WL

更新日期：2005-04-01 00:00:00

abstract：:Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

journal_title：Expert review of anticancer therapy

authors： Macafee DA,Maxwell-Armstrong C,Scholefield JH

更新日期：2003-08-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effecti...

journal_title：Expert review of anticancer therapy

authors： Battaglin F,Puccini A,Intini R,Schirripa M,Ferro A,Bergamo F,Lonardi S,Zagonel V,Lenz HJ,Loupakis F

更新日期：2018-03-01 00:00:00

abstract：:Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combin...

journal_title：Expert review of anticancer therapy

authors： Danson SJ,Middleton MR

更新日期：2001-06-01 00:00:00

abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (RCC). Drugs such as sorafenib, sunitinib and pazopanib act on the VEGF receptor pathway, but they can also inhibit other kinases, resulting in off-target toxicities. Tivozanib was developed due to its potency and selectivi...

journal_title：Expert review of anticancer therapy

authors： Wong HH,Eisen T

更新日期：2013-06-01 00:00:00

abstract：:The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

journal_title：Expert review of anticancer therapy

authors： Shen P,Stewart JH,Levine EA

更新日期：2008-11-01 00:00:00

abstract：:The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

journal_title：Expert review of anticancer therapy

authors： van Kempen LC

更新日期：2011-06-01 00:00:00